替比夫定与恩替卡韦对阿德福韦酯相关肾损害的慢性乙型肝炎患者肾功能改善效果比较及其影响因素

替比夫定与恩替卡韦对阿德福韦酯相关肾损害的慢性乙型肝炎患者肾功能改善效果比较及其影响因素
刘宇;滕春玲;张萍;杜漫;王慧雯;李慧娇;郭莉;曹汴川;王荣明;吴育龙;江建宁
【期刊名称】《广西医学》
【年(卷),期】2017(039)004
【摘要】目的比较替比夫定(LdT)与恩替卡韦(ETV)对阿德福韦酯(ADV)相关肾损害的慢性乙型肝炎(CHB)患者肾功能的改善效果并探讨其影响因素.方法阿德福韦酯相关肾损害的CHB或乙型肝炎肝硬化患者41例,分为LAT组(n=21)和ETV组(n=20),停阿德福韦酯后分别给予替比夫定和恩替卡韦抗病毒治疗,疗程均为24周.比较两组治疗前后肾功能的变化情况,并分析其影响因素.结果两组基线估算肾小球滤过率(eGFR)比较差异无统计学意义(P＞0.05),治疗24周后两组eGFR较治疗前均有改善,且LdT组改善程度优于ETV组(P均＜0.05).多因素logistic回归分析结果显示,基线eGFR＜60 ml·min-1·1.73 m-2和LdT方案是肾功能改善的影响因素(P均＜0.05).结论替比夫定对阿德福韦酯相关肾损害的CHB肾功能改善效果更为明显,且对于基线eGFR＜60 ml·min-·1.73 m-2的患者其改善效果更
好.%Objective To compare the clinical efficacy between telbivudine(LdT) and entecavir(ETV) on renal function recovery in chronic hepatitis B (CHB) patients with adefovir dipivoxil (ADV)-associated renal damage,and to investigate its influence factors.Methods A total of 41 CHB or liver cirrhosis due to hepatitis B patients with ADV-associated renal damage were divided into LdT group (n =21) and ETV group(n =20).The two groups were given LdT and ETV respectively after ADV withdrawal,and the
treatment lasted for 24 weeks.The baseline and the variation of renal function after treatment were compared between the two groups,and the influence factors were analyzed.Results There was no significant difference in estimated glomerular filtration rate(eGFR) between the two groups at baseline(P ＞ 0.05),but the eGFRs were improved distinctly after 24 weeks of treatment in both groups compared to those before treatment,and the extent of eGFR improvement was more significant in LdT group than that in ETV group (all P ＜ 0.05).The multivariate logistic regression analysis showed that the baseline eGFR ＜60 ml · min-1 · 1.73 m-2 and LdT regimen were the influence factors of renal function recovery(all P ＜
0.05).Conclusion LdT has more significant effects on renal function recovery in CHB patients with ADV-associated renal damage,especially for the patients whose baseline eGFRs are less than 60 ml · min-1 · 1.73 m-2.【总页数】4页(P440-443)
【作者】刘宇;滕春玲;张萍;杜漫;王慧雯;李慧娇;郭莉;曹汴川;王荣明;吴育龙;江建宁【作者单位】广西医科大学第一附属医院感染性疾病科,南宁市530021;广西医科大学第一附属医院感染性疾病科,南宁市530021;广西医科大学第一附属医院感染性疾病科,南宁市530021;广西医科大学第一附属医院感染性疾病科,南宁市530021;广西医科大学第一附属医院感染性疾病科,南宁市530021;广西医科大学第一附属医院感染性疾病科,南宁市530021;广西医科大学第一附属医院感染性疾病科,南宁市530021;广西医科大学第一附属医院感染性疾病科,南宁市530021;广西医科大学第一附属医院感染性疾病科,南宁市530021;广西医科大学第一附属医
院感染性疾病科,南宁市530021;广西医科大学第一附属医院感染性疾病科,南宁市530021
【正文语种】中文
【中图分类】R512.62
【相关文献】
1.阿德福韦酯联合拉米夫定和单独用恩替卡韦治疗阿德福韦酯耐药的慢性乙型肝炎患者的疗效比较 [J], 郝爱芹
2.替比夫定与恩替卡韦分别联合阿德福韦酯治疗对慢性乙型肝炎患者肝功能、肝纤维化指标、HBV-DNA水平及不良反应的影响 [J], 张丽丽;马欢;杨建波;罗玉君
3.单用恩替卡韦和拉米夫定联合阿德福韦酯对拉米夫定耐药的慢性乙型肝炎患者的疗效比较 [J], 刘志刚
4.单用恩替卡韦和拉米夫定联合阿德福韦酯对拉米夫定耐药的慢性乙型肝炎患者的疗效比较 [J], 刘志刚
5.3种核苷酸类药物对慢性乙型肝炎患者肾功能的影响及替比夫定对阿德福韦酯所致肾功能损伤的干预效果 [J], 常香荣;党双锁;江策
因版权原因，仅展示原文概要，查看原文内容请购买。